Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1296

1.

Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases.

Minta K, Brinkmalm G, Janelidze S, Sjödin S, Portelius E, Stomrud E, Zetterberg H, Blennow K, Hansson O, Andreasson U.

Alzheimers Res Ther. 2020 Feb 13;12(1):19. doi: 10.1186/s13195-020-00585-7.

2.

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia.

Llorens F, Hermann P, Villar-Piqué A, Diaz-Lucena D, Nägga K, Hansson O, Santana I, Schmitz M, Schmidt C, Varges D, Goebel S, Dumurgier J, Zetterberg H, Blennow K, Paquet C, Baldeiras I, Ferrer I, Zerr I.

Nat Commun. 2020 Jan 30;11(1):619. doi: 10.1038/s41467-020-14373-2.

3.

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2020 Jan 18. doi: 10.1007/s00401-019-02107-8. [Epub ahead of print]

PMID:
31955222
4.

Accelerated neuronal and synaptic maturation by BrainPhys medium increases Aβ secretion and alters Aβ peptide ratios from iPSC-derived cortical neurons.

Satir TM, Nazir FH, Vizlin-Hodzic D, Hardselius E, Blennow K, Wray S, Zetterberg H, Agholme L, Bergström P.

Sci Rep. 2020 Jan 17;10(1):601. doi: 10.1038/s41598-020-57516-7.

5.

Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data.

Wehrli PM, Michno W, Blennow K, Zetterberg H, Hanrieder J.

J Am Soc Mass Spectrom. 2019 Nov 1;30(11):2278-2288.

PMID:
31944737
6.

Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures.

Falgàs N, Ruiz-Peris M, Pérez-Millan A, Sala-Llonch R, Antonell A, Balasa M, Borrego-Écija S, Ramos-Campoy O, Augé JM, Castellví M, Tort-Merino A, Olives J, Fernández-Villullas G, Blennow K, Zetterberg H, Bargalló N, Lladó A, Sánchez-Valle R.

Hum Brain Mapp. 2020 Jan 16. doi: 10.1002/hbm.24925. [Epub ahead of print]

PMID:
31944489
7.

Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder.

Pillai A, Bruno D, Nierenberg J, Pandya C, Feng T, Reichert C, Ramos-Cejudo J, Osorio R, Zetterberg H, Blennow K, Pomara N.

Biomark Neuropsychiatry. 2019 Dec;1. pii: 100007. doi: 10.1016/j.bionps.2019.100007. Epub 2019 Nov 13.

8.

Neuroinflammatory markers associate with cognitive decline after major surgery: Findings of an explorative study.

Danielson M, Wiklund A, Granath F, Blennow K, Mkrtchian S, Nellgård B, Oras J, Jonsson Fagerlund M, Granström A, Schening A, Rasmussen LS, Erlandsson Harris H, Zetterberg H, Ricksten SE, Eriksson LI.

Ann Neurol. 2020 Mar;87(3):370-382. doi: 10.1002/ana.25678. Epub 2020 Jan 25.

PMID:
31930549
9.

Cerebrospinal Fluid Levels of Interleukin-8 in Delirium, Dementia, and Cognitively Healthy Patients.

Sajjad MU, Blennow K, Knapskog AB, Idland AV, Chaudhry FA, Wyller TB, Zetterberg H, Watne LO.

J Alzheimers Dis. 2020 Jan 6. doi: 10.3233/JAD-190941. [Epub ahead of print]

PMID:
31929159
10.

Circulating levels of vascular endothelial growth factor and post-stroke long-term functional outcome.

Åberg ND, Wall A, Anger O, Jood K, Andreasson U, Blennow K, Zetterberg H, Isgaard J, Jern C, Svensson J.

Acta Neurol Scand. 2020 Jan 9. doi: 10.1111/ane.13219. [Epub ahead of print]

PMID:
31919840
11.
12.

Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men.

Benedict C, Blennow K, Zetterberg H, Cedernaes J.

Neurology. 2020 Jan 8. pii: 10.1212/WNL.0000000000008866. doi: 10.1212/WNL.0000000000008866. [Epub ahead of print]

PMID:
31915189
13.

Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings.

Vermunt L, Muniz-Terrera G, Ter Meulen L, Veal C, Blennow K, Campbell A, Carrié I, Delrieu J, Fauria K, Huesa Rodríguez G, Ingala S, Jenkins N, Molinuevo JL, Ousset PJ, Porteous D, Prins ND, Solomon A, Tom BD, Zetterberg H, Zwan M, Ritchie CW, Scheltens P, Luscan G, Brookes AJ, Visser PJ; IMI-EPAD collaborators.

Alzheimers Res Ther. 2020 Jan 6;12(1):8. doi: 10.1186/s13195-019-0576-y.

14.

Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease.

Parbo P, Madsen LS, Ismail R, Zetterberg H, Blennow K, Eskildsen SF, Vorup-Jensen T, Brooks DJ.

Alzheimers Res Ther. 2020 Jan 2;12(1):3. doi: 10.1186/s13195-019-0574-0.

15.

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort.

Stamate D, Kim M, Proitsi P, Westwood S, Baird A, Nevado-Holgado A, Hye A, Bos I, Vos SJB, Vandenberghe R, Teunissen CE, Kate MT, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Engelborghs S, Sleegers K, Bordet R, Ramit L, Kettunen P, Tsolaki M, Verhey F, Alcolea D, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement (N Y). 2019 Dec 18;5:933-938. doi: 10.1016/j.trci.2019.11.001. eCollection 2019.

16.

Glycan biomarkers for Alzheimer disease correlate with T-tau and P-tau in cerebrospinal fluid in subjective cognitive impairment.

Schedin-Weiss S, Gaunitz S, Sui P, Chen Q, Haslam SM, Blennow K, Winblad B, Dell A, Tjernberg LO.

FEBS J. 2019 Dec 30. doi: 10.1111/febs.15197. [Epub ahead of print]

PMID:
31889402
17.

Longitudinal change in regional brain volumes with exposure to repetitive head impacts.

Bernick C, Shan G, Zetterberg H, Banks S, Mishra VR, Bekris L, Leverenz JB, Blennow K.

Neurology. 2020 Jan 21;94(3):e232-e240. doi: 10.1212/WNL.0000000000008817. Epub 2019 Dec 23.

PMID:
31871218
18.

Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep.

Zetterberg H, Bozzetta E, Favole A, Corona C, Cavarretta MC, Ingravalle F, Blennow K, Pocchiari M, Meloni D.

PLoS One. 2019 Dec 19;14(12):e0226697. doi: 10.1371/journal.pone.0226697. eCollection 2019.

19.

CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.

Clarke MTM, Brinkmalm A, Foiani MS, Woollacott IOC, Heller C, Heslegrave A, Keshavan A, Fox NC, Schott JM, Warren JD, Blennow K, Zetterberg H, Rohrer JD.

Alzheimers Res Ther. 2019 Dec 17;11(1):105. doi: 10.1186/s13195-019-0564-2.

20.

An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead.

Simrén J, Ashton NJ, Blennow K, Zetterberg H.

Curr Opin Neurobiol. 2019 Dec 12;61:29-39. doi: 10.1016/j.conb.2019.11.019. [Epub ahead of print] Review.

PMID:
31838254
21.

Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.

Hall S, Janelidze S, Zetterberg H, Brix B, Mattsson N, Surova Y, Blennow K, Hansson O.

Mov Disord. 2019 Dec 13. doi: 10.1002/mds.27950. [Epub ahead of print]

PMID:
31837067
22.

Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.

Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, Wahl S, Eichenlaub U, Lifke V, Simon M, Trojanowski JQ, Hansson O.

Sci Rep. 2019 Dec 13;9(1):19024. doi: 10.1038/s41598-019-54204-z.

23.

Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.

Blennow K, Chen C, Cicognola C, Wildsmith KR, Manser PT, Bohorquez SMS, Zhang Z, Xie B, Peng J, Hansson O, Kvartsberg H, Portelius E, Zetterberg H, Lashley T, Brinkmalm G, Kerchner GA, Weimer RM, Ye K, Höglund K.

Brain. 2020 Feb 1;143(2):650-660. doi: 10.1093/brain/awz346.

PMID:
31834365
24.

Salivary Biomarkers for Alzheimer's Disease and Related Disorders.

Ashton NJ, Ide M, Zetterberg H, Blennow K.

Neurol Ther. 2019 Dec;8(Suppl 2):83-94. doi: 10.1007/s40120-019-00168-1. Epub 2019 Dec 12. Review.

25.

Peripheral Biomarkers for Alzheimer's Disease: Update and Progress.

Sabbagh MN, Blennow K.

Neurol Ther. 2019 Dec;8(Suppl 2):33-36. doi: 10.1007/s40120-019-00171-6. Epub 2019 Dec 12. No abstract available.

26.

Repeated lumbar punctures within 3 days may affect CSF biomarker levels.

Olsson M, Ärlig J, Hedner J, Blennow K, Zetterberg H.

Fluids Barriers CNS. 2019 Dec 13;16(1):37. doi: 10.1186/s12987-019-0157-2.

27.

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.

Hermansson L, Yilmaz A, Price RW, Nilsson S, McCallister S, Makadzange T, Das M, Zetterberg H, Blennow K, Gisslen M.

PLoS One. 2019 Dec 11;14(12):e0226276. doi: 10.1371/journal.pone.0226276. eCollection 2019.

28.

CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults.

Halaas NB, Henjum K, Blennow K, Dakhil S, Idland AV, Nilsson LN, Sederevicius D, Vidal-Piñeiro D, Walhovd KB, Wyller TB, Zetterberg H, Watne LO, Fjell AM.

Cereb Cortex. 2019 Dec 8. pii: bhz240. doi: 10.1093/cercor/bhz240. [Epub ahead of print]

PMID:
31812991
29.

Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry.

Teunissen C, Parnetti L, Blennow K, Otto M.

Clin Chim Acta. 2020 Mar;502:199-200. doi: 10.1016/j.cca.2019.12.005. Epub 2019 Dec 6. No abstract available.

PMID:
31812757
30.

Postoperative delirium is associated with increased plasma neurofilament light.

Casey CP, Lindroth H, Mohanty R, Farahbakhsh Z, Ballweg T, Twadell S, Miller S, Krause B, Prabhakaran V, Blennow K, Zetterberg H, Sanders RD.

Brain. 2020 Jan 1;143(1):47-54. doi: 10.1093/brain/awz354.

PMID:
31802104
31.

Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease.

Cavedo E, Lista S, Houot M, Vergallo A, Grothe MJ, Teipel S, Zetterberg H, Blennow K, Habert MO, Potier MC, Dubois B, Hampel H; INSIGHT-preAD Study Group and the Alzheimer Precision Medicine Initiative.

Neurology. 2020 Jan 7;94(1):e30-e41. doi: 10.1212/WNL.0000000000008696. Epub 2019 Dec 4.

PMID:
31801830
32.

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.

Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sanchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, Hodges AK, Zetterberg H.

Alzheimers Res Ther. 2019 Nov 28;11(1):94. doi: 10.1186/s13195-019-0545-5.

33.

The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid.

Kranaster L, Hoyer C, Mindt S, Neumaier M, Müller N, Zill P, Schwarz MJ, Moll N, Lutz B, Bindila L, Zerr I, Schmitz M, Blennow K, Zetterberg H, Haffner D, Leifheit-Nestler M, Ozbalci C, Sartorius A.

Eur Arch Psychiatry Clin Neurosci. 2019 Nov 23. doi: 10.1007/s00406-019-01086-x. [Epub ahead of print]

PMID:
31760473
34.

Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study.

Neth BJ, Mintz A, Whitlow C, Jung Y, Solingapuram Sai K, Register TC, Kellar D, Lockhart SN, Hoscheidt S, Maldjian J, Heslegrave AJ, Blennow K, Cunnane SC, Castellano CA, Zetterberg H, Craft S.

Neurobiol Aging. 2020 Feb;86:54-63. doi: 10.1016/j.neurobiolaging.2019.09.015. Epub 2019 Sep 26.

PMID:
31757576
35.

Corrigendum: Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects.

Lue LF, Pai MC, Chen TF, Hu CJ, Huang LK, Lin WC, Wu CC, Jeng JS, Blennow K, Sabbagh MN, Yan SH, Wang PN, Yang SY, Hatsuta H, Morimoto S, Takeda A, Itoh Y, Liu J, Xie H, Chiu MJ.

Front Aging Neurosci. 2019 Nov 8;11:292. doi: 10.3389/fnagi.2019.00292. eCollection 2019.

36.

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.

Sandelius Å, Sandgren S, Axelsson M, Malmeström C, Novakova L, Kostanjevecki V, Vandijck M, Blennow K, Zetterberg H, Lycke J.

Sci Rep. 2019 Nov 21;9(1):17309. doi: 10.1038/s41598-019-54032-1.

37.

Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies.

Vogels T, Leuzy A, Cicognola C, Ashton NJ, Smolek T, Novak M, Blennow K, Zetterberg H, Hromadka T, Zilka N, Schöll M.

Biol Psychiatry. 2019 Oct 3. pii: S0006-3223(19)31744-5. doi: 10.1016/j.biopsych.2019.09.019. [Epub ahead of print] Review.

38.

Detection of early-stage Alzheimer's pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients.

DeMarshall C, Oh E, Kheirkhah R, Sieber F, Zetterberg H, Blennow K, Nagele RG.

PLoS One. 2019 Nov 15;14(11):e0225178. doi: 10.1371/journal.pone.0225178. eCollection 2019.

39.

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease.

Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, Eichenlaub U, Dage JL, Chai X, Blennow K, Mattsson N, Hansson O.

EMBO Mol Med. 2019 Dec;11(12):e11170. doi: 10.15252/emmm.201911170. Epub 2019 Nov 11.

40.

Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition.

Osborn KE, Khan OA, Kresge HA, Bown CW, Liu D, Moore EE, Gifford KA, Acosta LMY, Bell SP, Hohman TJ, Blennow K, Zetterberg H, Jefferson AL.

Alzheimers Dement (Amst). 2019 Oct 22;11:700-709. doi: 10.1016/j.dadm.2019.08.008. eCollection 2019 Dec.

41.

Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.

Blennow K, Zetterberg H.

Prog Mol Biol Transl Sci. 2019;168:3-23. doi: 10.1016/bs.pmbts.2019.07.006. Epub 2019 Jul 24.

PMID:
31699324
42.

Alzheimer's Disease Composite Score: A Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease.

Hendrix SB, Soininen H, van Hees AMJ, Ellison N, Visser PJ, Solomon A, Attali A, Blennow K, Kivipelto M, Hartmann T.

J Prev Alzheimers Dis. 2019;6(4):232-236. doi: 10.14283/jpad.2019.33.

PMID:
31686094
43.

Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.

Arboleda-Velasquez JF, Lopera F, O'Hare M, Delgado-Tirado S, Marino C, Chmielewska N, Saez-Torres KL, Amarnani D, Schultz AP, Sperling RA, Leyton-Cifuentes D, Chen K, Baena A, Aguillon D, Rios-Romenets S, Giraldo M, Guzmán-Vélez E, Norton DJ, Pardilla-Delgado E, Artola A, Sanchez JS, Acosta-Uribe J, Lalli M, Kosik KS, Huentelman MJ, Zetterberg H, Blennow K, Reiman RA, Luo J, Chen Y, Thiyyagura P, Su Y, Jun GR, Naymik M, Gai X, Bootwalla M, Ji J, Shen L, Miller JB, Kim LA, Tariot PN, Johnson KA, Reiman EM, Quiroz YT.

Nat Med. 2019 Nov;25(11):1680-1683. doi: 10.1038/s41591-019-0611-3. Epub 2019 Nov 4.

PMID:
31686034
44.

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals.

Benedet AL, Ashton NJ, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS, Therriault J, Savard M, Chamoun M, Schöll M, Zimmer ER, Gauthier S, Labbe A, Zetterberg H, Blennow K, Neto PR.

Alzheimers Dement (Amst). 2019 Sep 27;11:679-689. doi: 10.1016/j.dadm.2019.08.002. eCollection 2019 Dec.

45.

Measuring longitudinal cognition: Individual tests versus composites.

Jonaitis EM, Koscik RL, Clark LR, Ma Y, Betthauser TJ, Berman SE, Allison SL, Mueller KD, Hermann BP, Van Hulle CA, Christian BT, Bendlin BB, Blennow K, Zetterberg H, Carlsson CM, Asthana S, Johnson SC.

Alzheimers Dement (Amst). 2019 Jan 11;11:74-84. doi: 10.1016/j.dadm.2018.11.006. eCollection 2019 Dec.

46.

Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration.

Höglund K, Schussler N, Kvartsberg H, Smailovic U, Brinkmalm G, Liman V, Becker B, Zetterberg H, Cedazo-Minguez A, Janelidze S, Lefevre IA, Eyquem S, Hansson O, Blennow K.

Neurobiol Dis. 2020 Feb;134:104645. doi: 10.1016/j.nbd.2019.104645. Epub 2019 Oct 25.

47.

Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.

Antonell A, Tort-Merino A, Ríos J, Balasa M, Borrego-Écija S, Auge JM, Muñoz-García C, Bosch B, Falgàs N, Rami L, Ramos-Campoy O, Blennow K, Zetterberg H, Molinuevo JL, Lladó A, Sánchez-Valle R.

Alzheimers Dement. 2020 Feb;16(2):262-272. doi: 10.1016/j.jalz.2019.09.001. Epub 2020 Jan 6.

PMID:
31668967
48.

Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin.

Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Vemuri P, Machulda MM, Graff-Radford J, Knopman DS, Jack CR Jr, Petersen RC, Kern S.

Alzheimers Dement. 2019 Nov;15(11):1437-1447. doi: 10.1016/j.jalz.2019.07.009. Epub 2019 Oct 23.

PMID:
31668594
49.

Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas.

Hepner A, Porter J, Hare F, Nasir SS, Zetterberg H, Blennow K, Martin MG.

World J Oncol. 2019 Oct;10(4-5):169-175. doi: 10.14740/wjon1228. Epub 2019 Sep 20.

50.

Chemical imaging of evolving amyloid plaque pathology and associated Aβ peptide aggregation in a transgenic mouse model of Alzheimer's disease.

Michno W, Wehrli P, Meier SR, Sehlin D, Syvänen S, Zetterberg H, Blennow K, Hanrieder J.

J Neurochem. 2019 Oct 12. doi: 10.1111/jnc.14888. [Epub ahead of print]

PMID:
31605538

Supplemental Content

Loading ...
Support Center